| Name | Title | Contact Details |
|---|
Veritas Health Solutions is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wilderness Adventure At Eagle is a New Castle, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Service and value set Medical Mutual and its Family of Companies apart. A trusted insurer for 80 years, we are the oldest and largest health insurance company headquartered in the state of Ohio. As a mutual company, we operate for the benefit of our members without needing to meet the demands of stockholders or Wall Street analysts. Instead, we focus on developing products and services that allow us to better serve our customers and the communities around us and help our members achieve their best possible health and quality of life. The work you do and the team you choose has a huge impact on your life. If you are seeking a challenging and supportive work environment that will help you be your best, then you belong with an organization that values high performance and ambition — Medical Mutual. Our reputation of great service is the result of an exceptional team effort from our dedicated employees. We offer an attractive compensation package that includes excellent benefits, a 401K plan with a company match, an on-site fitness center, employee wellness programs, professional development and much more. Discover Medical Mutual and all we have to offer.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Crunch is a No Judgment Gym that believes in making serious exercise fun by fusing fitness and entertainment. Join Crunch for all your fitness needs!